Company / Interest Expense
Esperion Therapeutics, Inc. Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$59.0M
FY2023
5-year range
$46.4M / $59.0M
FY2019-FY2023
Trend
+3.8%
vs FY2022
Sector context
#12 of 44
Health Care
What the data says
At $59M, Esperion Therapeutics, Inc.'s interest expense ranks #33 of 44 in the Health Care sector. Interest Expense has increased for 5 consecutive years, from $28,000 in FY2018 to $59M in FY2023.
Based on SEC 10-K filings.
$59M in FY2023 with a 5-year CAGR of +362.1%.
Increased from $46M to $59M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +37.5%
- 5-Year CAGR
- +362.1%
- 10-Year CAGR
- -
Sector benchmark
#33 of 44 in Health CareTop 73% of 44This company $59.0M Sector average $291.0M
▼
-79.7% below sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s interest expense has grown for 5 consecutive years.
- 5-year CAGR of +362.1%, indicating consistent growth.
- In FY2023, interest expense increased 3.8% year-over-year.
- Ranks #12 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $59.0M | +3.8% |
| FY2022 | $56.8M | +22.6% |
| FY2021 | $46.4M | +104.5% |
| FY2020 | $22.7M | +179.2% |
| FY2019 | $8.1M | +28900.0% |
| FY2018 | $28.0K | -85.9% |
| FY2017 | $198.0K | -47.3% |
| FY2016 | $376.0K | -27.7% |
As of FY2023 · SEC 10-K · Updated Jul 2, 2026